The Effect of Sputum Culture Results on The Duration of Hospitalization in Patients with Bronchiectasis

Yıl 2019, Cilt 16, Sayı 3, 413 - 416, 25.12.2019

İclal HOCANLI Mehmet KABAK Barış ÇİL Ahmet DOBLAN İdris KIRHAN

https://doi.org/10.35440/hutfd.625999

Öz

Background: The aim of this study is to investigate whether sputum culture results (treatment revision according to culture results) have an effect on the duration of hospitalization in patients who were followed up with the diagnosis of bronchiectasis in our clinic.

Materials and Methods: The laboratory and radiological data of 23 patients who were followed up with the diagnosis of bronchiectasis in the chest diseases clinic between January 2018-December 2018 were analyzed retrospectively. Demographic features, the duration of hospitalization, the used antibiotics and antibiotic changes according to the culture results were recorded for all patients.  The duration of hospitalization of patients with and without culture growth was compared. In addition, the culture growing group was evaluated in itself according to the growing microorganism type in terms of the duration of hospitalization.

Results: While 39.1% (9 patients) of the patients had culture growth, 60.9% (14 patients) had no culture (14 patients). Klebsiella pneumonia was detected in the culture of 4 patients, pseudomonas aeruginosa in the culture of 4 patients and mycobacterium tuberculosis in the culture of 1 patient. Although the duration of hospitalization was longer in patients with (10.1 ± 5.1 days) than those without culture growth (7.8 ± 5.5 days), there was no significant difference between two groups (p= 0.135). However, when patients with culture growth were compared according to the microorganism type; it was detected that patients with pseudomonas aeruginosa growth in the culture had significantly longer duration of hospitalization.

Conclusion: Pseudomonas aeruginosa is one of the most common grow microorganisms in sputum cultures of patients with bronchiectasis. This factor increases the duration of hospitalization of patients.

Bronşektazi Tanılı Hastaların Balgam Kültür Sonuçlarının Hastanede Kalış Süresine Etkisi

Öz

Amaç: Bu çalışmanın amacı, kliniğimizde bronşektazi tanısıyla takip edilmiş hastaların balgam kültür sonuçlarının hastanede kalış süresi üzerine etkisinin olup olmadığını araştırmaktır. 

Materyal ve metod: Ocak 2018-aralık 2018 tarihleri arasında göğüs hastalıkları kliniğinde bronşektazi tanısyla takip edilen,  23 hastanın laboratuvar ve radyolojik verileri retrospektif olarak incelendi.

Bulgular: Hastaların %39,1' de  kültürde üreme olurken (9 hasta), %60,1'de kültürde üreme olmadı (14 hasta). 4 hastanın kültüründe klebsiella pnömoni, yine 4 hastanın kültüründe  psödomonas aeruginosa ve 1 hastanın kültüründe de  myocobacterıum tuberculosis üredi.kültür üremesi olan hastalar ile kültür üremesi olmayan hastalar hastane yatış süreleri karşılaştırıldı.Kültürde üremesi saptanan hastalarda (10.1±5.1 gün), kültürde üremesi saptanmayan hastalara (7.8±5.5 gün) göre hastane yatış süresi daha uzun olmakla beraber istatiksel olarak anlamlı bir farklılık tespit edilmedi (p=0.135). Ancak kültürde  psödomonas aeruginosa üremesi olanların hastanede kalış süresi daha uzun ve istatiksel olarak ta anlamlı idi.

Sonuç: Bronşektazi tanılı hastalarda kolonizasyon ve/veya enfeksiyon sık görülmektedir. Balgam kültürlerinde en sık üreyen etkenlerden biri pseudomonas aeruginosadır ve bu etken hastane yatış sürelerini arttırmaktadır. Çalışmamızda az sayıda olgu olmasına rağmen, literatür verilerine  benzer sonuçlar elde edilmiştir. Ancak daha etkili değerlendirmeler yapabilmek için hasta sayısının daha yoğun olduğu benzer çalışmalara ihtiyaç vardır.

Anahtar Kelimeler

bronşektazi, balgam kültürü, enfeksiyon

Kaynakça

• 1. Fishman AP. Bronchiectasis. In: Fishman AP, Elias JA, Fishman JA, et al (eds). Fishman’s Pulmonary Diseases and Disorders. 3rd ed. Vol 2. International Edition: Mc Graw-Hill, 1998: 2045-69.
• 2. Angrill J, Agusti C, Torres A. Bronchiectasis. Curr Opin Infect Dis 2001 ;14(2):193-7.
• 3. Barker A. Bronchiectasis. N Engl J Med 2002;346(18):1383-93.
• 4. N Kömüs, KC Tertemiz, A Akkoçlu, Z Gülay, E Yılmaz. Pseudomonas aeruginosa colonisation in bronchiectatic patients and clinical reflections. Tüberküloz ve Toraks Dergisi 2006; 54(4): 355-362.
• 5. Martinez-Garcia MA, Soler-Cataluna JJ, Donat Sanz Y, Catalan Serra P, Ag¬ramunt Lerma M, Ballestin Vicente J, et al. Factors associated with bronc¬hiectasis in patients with COPD. Chest 2011;140(5):1130-1137. doi: 10.1378/chest.10-1758.
• 6. Martinez-Garcia MA, de la Rosa D, Soler-Cataluna JJ, Donat-Sanz Y, Cata¬lan Serra P, Agramunt Lerma M, et al. Prognostic Value of Bronchiectasis in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2013 15;187(8):823-31. doi: 10.1164/rccm.201208-1518OC.
• 7. Patel IS, Vlahos I, Wilkinson TM, Lloyd-Owen SJ, Donaldson GC, Wilks M, et al. Bronchiectasis, exacerbation indices and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170(4):400-7.
• 8. Asthma And Bronchıectasıs Exacerbatıon Bei Mao, Jia-Wei Yang, Hai-Wen Lu, Jin-Fu Xu Eur Respir J. 2016;47(6):1680-6.
• 9. Asthma as aetiology of bronchiectasis in Finland. Mäntylä J, Mazur W, Törölä T, Bergman P, Saarinen T, Kauppi P. Respir Med. 2019;152:105-111. doi: 10.1016/j.rmed.2019.04.022.
• 10. Kartagener’s syndrome. Rodolfo Mendes Queiroz , Fred Bernardes Filho. Pan Afr Med J. 2018; 29: 160. doi: 10.11604/pamj.2018.29.160.14927.
• 11. Angrill J, Agustí C, de Celis R, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 2002; 57:15–9.
• 12. King PT, Holdsworth SR, Freezer NJ, et al. Microbiologic follow-up study in adult bronchiectasis. Respir Med 2007;101(8):1633-8.
• 13. Pang JA, Cheng A, Chan HS, et al. The bacteriology of bronchiectasis in Hong Kong investigated by protected catheter brush and broncoalveolar lavage. Am Rev Respir Dis 1989 ;139(1):14-7.
• 14. Wilson CB, Jones PW, O’Leary CJ, Hansell DM, Cole PJ, Wilson R. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1997;10(8):1754-60.
• 15. Rogers GB, Zain NM, Bruce KD, et al. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. Ann Am Thorac Soc 2014 May;11(4):496-503. doi: 10.1513/AnnalsATS.201310-335OC.
• 16. Ringshausen FC, de Roux A, Pletz MW, Hämäläinen N, Welte T, Rademacher J. Bronchiectasis-associated hospitalizations in germany, 2005–2011: A population-based study of disease burden and trends. PLoS ONE 2013, 8, e71109. doi: 10.1371/journal.pone.0071109.
• 17. Seitz, AE, Olivier N, Steiner CA, Montes de Oca R, Holland SM, Prevots DR. Trends and burden of bronchiectasis-associated hospitalizations in the united states, 1993–2006. Chest 2010 Oct;138(4):944-9. doi: 10.1378/chest.10-0099.
• 18. Evans DJ, Bara AI, Greenstone M. Prolonged antibiotics for purulent bronchiectasis in children and adults. Cochrane Database Syst Rev 2007;18 (2).
• 19. Cymbala AA, Edmonds LC, Bauer MA, Jederlinic PJ, May JJ, Victory JM, et al. The diseasemodifying effects of twice weekly oral azithromycin in patients with bronchiectasis. Treat Respir Med 2005;4(2):117-22.